lifestyle.sourcefed.com

Author: Artelo Biosciences

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

April 7, 2026
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

March 30, 2026
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

March 27, 2026
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

March 25, 2026
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

March 18, 2026
Artelo Biosciences Announces Reverse Stock Split

March 6, 2026
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

February 24, 2026